AYTU BIOPHARMA, INC(AYTU)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,727 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AYTU Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for AYTU BIOPHARMA, INC (AYTU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AYTU at 23.4/100 on a 32-signal composite quality model, placing it at rank #2,727 of 2,962 stocks — the bottom half of the AI-ranked universe. AYTU scores in the top quartile across institutional flow (99.5). Areas of concern include revenue growth (6.8) and balance sheet strength (8.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), AYTU BIOPHARMA, INC reports quarterly revenue of $12.4M, net income of $-5.6M, an operating margin of -32.8%. Top institutional holders of AYTU by reported 13-F value include Stonepine Capital Management, Nantahala Capital Management, AWM Investment Company, based on the most recent SEC filings. AYTU trades on the Nasdaq exchange and files with the SEC under CIK 1385818. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AYTU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AYTU BIOPHARMA, INC directly from SEC EDGAR. AYTU BIOPHARMA, INC's 13F Pro composite quality score has ranged between 16 and 43 since 2021, currently 23.4 — a declining long-term trajectory across 66 quarterly and live scoring snapshots.
Revenue
Q1 2026
$12.4M
Net Income
Q1 2026
$-5.6M
Free Cash Flow
Q1 2026
$-4.2M
Operating Margin
Q1 2026
-32.8%
ROIC
Q1 2026
-33.6%
D/E Ratio
Q1 2026
0.38
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1.8% YoYNet Income
+14.4% YoYOperating Income
-392.0% YoYEPS (Diluted)
Total Assets
+5.2% YoYTotal Debt
-14.0% YoYOp. Cash Flow
-39.6% YoYFree Cash Flow
-26.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $66.4M +1.8% | $65.2M -39.3% | $107.4M +11.1% | $96.7M +47.3% | $65.6M +137.5% | $27.6M |
| Net Income | $-13.6M +14.4% | $-15.8M +7.1% | $-17.1M +84.3% | $-108.8M -86.6% | $-58.3M -327.9% | $-13.6M |
| Operating Income | $-7.8M -392.0% | $-1.6M +90.7% | $-17.1M +84.5% | $-109.9M -86.7% | $-58.9M -178.6% | $-21.1M |
| EPS (Diluted) | — | — | $-5.11 +93.1% | $-74.01 -2026.7% | $-3.48 | — |
| Total Assets | $124.2M +5.2% | $118.1M -13.5% | $136.5M -0.8% | $137.6M -48.2% | $265.7M +73.3% | $153.3M |
| Total Debt | $14.6M -14.0% | $17.0M +1.5% | $16.7M -11.5% | $18.9M +12.2% | $16.8M +757.8% | $2.0M |
| Operating Cash Flow | $-1.9M -39.6% | $-1.4M +72.9% | $-5.1M +82.2% | $-28.8M -11.0% | $-26.0M +8.5% | $-28.4M |
| Free Cash Flow | $-2.2M -26.1% | $-1.7M | — | $-28.8M -1.8% | $-28.3M +0.2% | $-28.4M |
Get alerted when AYTU's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AYTU BIOPHARMA, INC including:
Top Institutional Holders of AYTU
Stonepine Capital Management, LLC
$9.6M4,990,238 shNantahala Capital Management, LLC
$2.3M1,086,812 shAWM Investment Company, Inc.
$1.3M619,574 shVANGUARD CAPITAL MANAGEMENT LLC
$561.5K261,146 shCROWN ADVISORS MANAGEMENT, INC.
$430.0K200,000 shDIADEMA PARTNERS LP
$319.4K148,546 shTWO SIGMA INVESTMENTS, LP
$226.5K105,326 shRENAISSANCE TECHNOLOGIES LLC
$225.4K104,823 shGEODE CAPITAL MANAGEMENT, LLC
$201.4K93,647 shCITADEL ADVISORS LLC
$106.2K49,414 sh
| Fund | Value | Shares |
|---|---|---|
| Stonepine Capital Management, LLC | $9.6M | 4,990,238 |
| Nantahala Capital Management, LLC | $2.3M | 1,086,812 |
| AWM Investment Company, Inc. | $1.3M | 619,574 |
| VANGUARD CAPITAL MANAGEMENT LLC | $561.5K | 261,146 |
| CROWN ADVISORS MANAGEMENT, INC. | $430.0K | 200,000 |
| DIADEMA PARTNERS LP | $319.4K | 148,546 |
| TWO SIGMA INVESTMENTS, LP | $226.5K | 105,326 |
| RENAISSANCE TECHNOLOGIES LLC | $225.4K | 104,823 |
| GEODE CAPITAL MANAGEMENT, LLC | $201.4K | 93,647 |
| CITADEL ADVISORS LLC | $106.2K | 49,414 |
Companies Similar to AYTU
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Inventiva S.A.
Xtant Medical Holdings, Inc.
DarioHealth Corp.
Evolus, Inc.
ROCKWELL MEDICAL, INC.
Pelthos Therapeutics Inc.
USANA HEALTH SCIENCES INC
Assertio Holdings, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AYTU on your watchlist
Track score changes the day AYTU BIOPHARMA, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AYTU a good stock to buy?
13F Pro's AI-powered analysis of AYTU BIOPHARMA, INC (AYTU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AYTU are available on the AYTU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AYTU is classified as a small company.
Which hedge funds own AYTU?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AYTU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AYTU BIOPHARMA, INC's investment landscape.